Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues

Zhalehjoo,Naghmeh; Shakiba,Yadollah; Panjehpour,Mojtaba

doi:10.3892/mmr.2016.5992

Gene expression profiles of CYP24A1 and CYP27B1 in malignant and normal breast tissues

Authors:
- Naghmeh Zhalehjoo
- Yadollah Shakiba
- Mojtaba Panjehpour
View Affiliations

Affiliations: Department of Clinical Biochemistry and Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 81746‑73461, Iran, Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 14176‑13151, Iran
Published online on: December 6, 2016 https://doi.org/10.3892/mmr.2016.5992
Pages: 467-473

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Active vitamin D has several antitumor effects, including prodifferentiative, antiproliferative and proapoptotic functions in a number of tissues via its binding to vitamin D receptor. The 24‑hydroxylase (CYP24A1) and 1‑hydroxylase (CYP27B1) enzymes are considered to be pivotal determinants of the local concentration of active vitamin D. The aim of the present study was to investigate the mRNA expression levels of the CYP24A1 and CYP27B1 genes in malignant and normal breast tissues. The tumor and adjacent normal tissue samples of 30 patients with breast cancer were acquired from the Iran National Tumor Bank, Imam Hospital (Tehran, Iran). RNA was extracted and, following cDNA synthesis, Taq‑Man quantitative polymerase chain reaction analysis was performed for CYP24A1 and CYP27B1. The results demonstrated that the mRNA expression of CYP27B1 was downregulated in the tumor tissues, compared with the adjacent normal tissues (P<0.01), whereas the mRNA expression of CYP24A1 was significantly upregulated in the tumor tissues (P<0.01). This major difference revealed that the normal breast tissues transcriptionally expressed CYP24A1 slightly. These results are suggestive of dysregulation of the vitamin D signaling and metabolic pathways during tumorigenesis in breast cancer. Local alterations in the anabolism and catabolism of active vitamin D in breast cancer by the CYP27B1 and CYP24A1 may impair its anticancer functions.

View Figures

View References

1	Colston KW, Lowe LC, Mansi JL and Campbell MJ: Vitamin D status and breast cancer risk. Anticancer Res. 26:2573–2580. 2006.PubMed/NCBI
2	Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, Momtahen AJ, Kashefi A and Ebrahimi M: Twenty years of breast cancer in Iran: Downstaging without a formal screening program. Ann Oncol. 22:93–97. 2011. View Article : Google Scholar : PubMed/NCBI
3	McCarthy K, Laban C, Bustin SA, Ogunkolade W, Khalaf S, Carpenter R and Jenkins PJ: Expression of 25-hydroxyvitamin D-1-alpha-hydroxylase and Vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Res. 29:155–157. 2009.PubMed/NCBI
4	Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC and Jurutka PW: Molecular mechanisms of vitamin D action. Calcif Tissue Int. 92:77–98. 2013. View Article : Google Scholar : PubMed/NCBI
5	Anderson MG, Nakane M, Ruan X, Kroeger PE and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 57:234–240. 2006. View Article : Google Scholar : PubMed/NCBI
6	Ordonez-Moran P, Larriba MJ, Pendas-Franco N, Aguilera O, Gonzalez-Sancho JM and Munoz A: Vitamin D and cancer: An update of in vitro and in vivo data. Front Biosci. 10:2723–2749. 2005. View Article : Google Scholar : PubMed/NCBI
7	Segersten U, Holm PK, Björklund P, Hessman O, Nordgren H, Binderup L, Akerström G and Hellman P: 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue. Breast Cancer Res. 7:R980–R986. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wang J and Jiang YF: Natural compounds as anticancer agents: Experimental evidence. World J Exp Med. 2:45–57. 2012. View Article : Google Scholar : PubMed/NCBI
9	Luo W, Hershberger PA, Trump DL and Johnson CS: 24-Hydroxylase in cancer: Impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol. 136:252–257. 2013. View Article : Google Scholar : PubMed/NCBI
10	Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G and Kállay E: The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem. 58:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chun RF, Liu PT, Modlin RL, Adams JS and Hewison M: Impact of vitamin D on immune function: Lessons learned from genome-wide analysis. Front Physiol. 5:1512014.PubMed/NCBI
12	Townsend K, Banwell CM, Guy M, Colston KW, Mansi JL, Stewart PM, Campbell MJ and Hewison M: Autocrine metabolism of vitamin D in normal and malignant breast tissue. Clin Cancer Res. 11:3579–3586. 2005. View Article : Google Scholar : PubMed/NCBI
13	Anderson PH, O'Loughlin PD, May BK and Morris HA: Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase-polymerase chain reaction. J Mol Endocrinol. 31:123–132. 2003. View Article : Google Scholar : PubMed/NCBI
14	Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB and Holick MF: The role of vitamin D in cancer prevention. Am J Public Health. 96:252–261. 2006. View Article : Google Scholar : PubMed/NCBI
15	Aung TT, Chandana SR, D'Silva KJ and Dimitrov NV: The role of vitamin D in breast cancer. Oncol Rev. 3:19–25. 2009. View Article : Google Scholar
16	Friedrich M, Diesing D, Cordes T, Fischer D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick MF and Reichrath J: Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res. 26:2615–2620. 2006.PubMed/NCBI
17	Fischer D, Becker S, Cordes T, Bücker B, Diedrich K, Friedrich M, Salehin D and Thill M: Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Res. 29:3641–3645. 2009.PubMed/NCBI
18	Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG and Colston KW: Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 41:1164–1169. 2005. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Evans SR, Nolla J, Hanfelt J, Shabahang M, Nauta RJ and Shchepotin IB: Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. Clin Cancer Res. 4:1591–1595. 1998.PubMed/NCBI
21	Fischer D, Thomé M, Becker S, Cordes T, Diedrich K, Friedrich M and Thill M: 25-Hydroxyvitamin D3 1alpha-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. Anticancer Res. 29:3627–3633. 2009.PubMed/NCBI
22	Fleet JC, DeSmet M, Johnson R and Li Y: Vitamin D and cancer: A review of molecular mechanisms. Biochem J. 441:61–76. 2012. View Article : Google Scholar : PubMed/NCBI
23	Welsh JE: Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol. 347:55–60. 2011. View Article : Google Scholar : PubMed/NCBI
24	Thill M, Hoellen F, Becker S, Dittimer C, Fischer D, Kümmel S, Salehin D, Friedrich M, Köster F, Diedrich K and Cordes T: Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells. Anticancer Res. 32:367–372. 2012.PubMed/NCBI
25	Ren S, Nguyen L, Wu S, Encinas C, Adams JS and Hewison M: Alternative splicing of vitamin D-24-hydroxylase: A novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem. 280:20604–20611. 2005. View Article : Google Scholar : PubMed/NCBI
26	Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, Inoue H and Mori M: Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol. 15:236–241. 2004. View Article : Google Scholar : PubMed/NCBI
27	Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI
28	Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D: Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet. 25:144–146. 2000. View Article : Google Scholar : PubMed/NCBI
29	Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL and Schmitt F: Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 10:4832010. View Article : Google Scholar : PubMed/NCBI
30	Grant WB: The likely role of vitamin D from solar ultraviolet-B irradiance in increasing cancer survival. Anticancer Res. 26:2605–2614. 2006.PubMed/NCBI
31	Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB and Hewison M: Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 28:46–55. 2013. View Article : Google Scholar : PubMed/NCBI